MX2019001937A - Métodos de tratamiento de trastornos del desarrollo con biguanidas. - Google Patents
Métodos de tratamiento de trastornos del desarrollo con biguanidas.Info
- Publication number
- MX2019001937A MX2019001937A MX2019001937A MX2019001937A MX2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A MX 2019001937 A MX2019001937 A MX 2019001937A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- disorder
- methods
- developmental disorders
- biguanides
- Prior art date
Links
- 208000012239 Developmental disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229940123208 Biguanide Drugs 0.000 title abstract 2
- 150000004283 biguanides Chemical class 0.000 title 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 2
- 201000003415 fragile X-associated tremor/ataxia syndrome Diseases 0.000 abstract 2
- 206010052075 Acquired epileptic aphasia Diseases 0.000 abstract 1
- 208000009575 Angelman syndrome Diseases 0.000 abstract 1
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 abstract 1
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 206010049644 Williams syndrome Diseases 0.000 abstract 1
- 229960004111 buformin Drugs 0.000 abstract 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 abstract 1
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960003243 phenformin Drugs 0.000 abstract 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376488P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047505 WO2018035408A1 (en) | 2016-08-18 | 2017-08-18 | Methods of treating developmental disorders with biguanides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001937A true MX2019001937A (es) | 2019-10-02 |
Family
ID=61190982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001937A MX2019001937A (es) | 2016-08-18 | 2017-08-18 | Métodos de tratamiento de trastornos del desarrollo con biguanidas. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10123979B2 (enExample) |
| EP (1) | EP3484452A4 (enExample) |
| JP (1) | JP2019524834A (enExample) |
| KR (1) | KR20190039974A (enExample) |
| CN (1) | CN109715144A (enExample) |
| AU (1) | AU2017313823A1 (enExample) |
| CA (1) | CA3033967A1 (enExample) |
| MX (1) | MX2019001937A (enExample) |
| WO (1) | WO2018035408A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970884A4 (en) | 2013-03-14 | 2016-11-02 | Univ Florida | DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS |
| WO2016196324A1 (en) | 2015-05-29 | 2016-12-08 | University Of Floridia Research Foundation, Inc. | Methods for diagnosing huntington's disease |
| US10940161B2 (en) | 2016-04-04 | 2021-03-09 | University Of Florida Research Foundation, Incorporated | Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation |
| WO2018035408A1 (en) | 2016-08-18 | 2018-02-22 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with biguanides |
| JP7526455B2 (ja) | 2017-04-17 | 2024-08-01 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節 |
| JP7350337B2 (ja) | 2017-09-26 | 2023-09-26 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用 |
| GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
| JP7620988B2 (ja) | 2019-09-20 | 2025-01-24 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出 |
| GB202008699D0 (en) * | 2020-06-09 | 2020-07-22 | Healx Ltd | Treatment |
| CN113318111A (zh) * | 2021-06-21 | 2021-08-31 | 浙江大学 | Nav1.1激动剂在制备治疗自闭症的药物中的应用 |
| EP4440560A1 (en) * | 2021-12-01 | 2024-10-09 | University Of Florida Research Foundation, Incorporated | Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US7214387B2 (en) * | 2002-08-02 | 2007-05-08 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| US20060147947A1 (en) * | 2002-12-04 | 2006-07-06 | Javier Apfeld | AMPK pathway components |
| US8252321B2 (en) * | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US20080188457A1 (en) * | 2007-02-02 | 2008-08-07 | Braincells, Inc. | Modulation of Neurogenesis with Biguanides and GSK3-beta Agents |
| CN102058888B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种治疗能量代谢异常的药物组合物和其应用 |
| WO2012081713A1 (ja) * | 2010-12-13 | 2012-06-21 | 学校法人福岡大学 | 血液脳関門障害症候群治療薬 |
| KR20160037169A (ko) * | 2013-06-26 | 2016-04-05 | 레트 신드롬 리서치 트러스트 | 레트 증후군 및 그를 위한 치료 |
| WO2018035408A1 (en) | 2016-08-18 | 2018-02-22 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with biguanides |
-
2017
- 2017-08-18 WO PCT/US2017/047505 patent/WO2018035408A1/en not_active Ceased
- 2017-08-18 CA CA3033967A patent/CA3033967A1/en not_active Abandoned
- 2017-08-18 AU AU2017313823A patent/AU2017313823A1/en not_active Abandoned
- 2017-08-18 EP EP17842173.1A patent/EP3484452A4/en not_active Withdrawn
- 2017-08-18 US US15/680,417 patent/US10123979B2/en active Active
- 2017-08-18 MX MX2019001937A patent/MX2019001937A/es unknown
- 2017-08-18 JP JP2019508879A patent/JP2019524834A/ja active Pending
- 2017-08-18 CN CN201780057960.3A patent/CN109715144A/zh active Pending
- 2017-08-18 KR KR1020197006647A patent/KR20190039974A/ko not_active Ceased
-
2018
- 2018-10-11 US US16/157,653 patent/US10426746B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190046480A1 (en) | 2019-02-14 |
| KR20190039974A (ko) | 2019-04-16 |
| JP2019524834A (ja) | 2019-09-05 |
| US10426746B2 (en) | 2019-10-01 |
| CN109715144A (zh) | 2019-05-03 |
| EP3484452A4 (en) | 2020-04-01 |
| CA3033967A1 (en) | 2018-02-22 |
| AU2017313823A1 (en) | 2019-02-28 |
| EP3484452A1 (en) | 2019-05-22 |
| US20180050001A1 (en) | 2018-02-22 |
| WO2018035408A1 (en) | 2018-02-22 |
| US10123979B2 (en) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001937A (es) | Métodos de tratamiento de trastornos del desarrollo con biguanidas. | |
| MX391708B (es) | Metodos para tratar trastornos del desarrollo con gaboxadol. | |
| WO2021217004A3 (en) | Methods and compositions for treating virus-associated inflammation | |
| WO2016200101A3 (ko) | 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| WO2018226758A3 (en) | METHODS FOR ENHANCED PRODUCTION AND ISOLATION OF CELL ORIGIN VESICLES AND TREATMENT OF INFLAMMATION AND NEUROLOGICAL DAMAGE | |
| WO2018004283A3 (ko) | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 | |
| UY36275A (es) | Compuestos aminopirimidinilo | |
| EA201491819A1 (ru) | Фармацевтические композиции для комбинированного лечения | |
| AR093705A1 (es) | Depsipeptido y sus usos | |
| ECSP17044282A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| WO2018224689A3 (en) | SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | |
| NZ748016A (en) | Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders | |
| WO2015104658A3 (en) | Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| MX2021005740A (es) | Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo. | |
| WO2016112875A3 (zh) | 二联苯衍生物及其应用 | |
| CO2017008426A2 (es) | Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico | |
| CA3011003A1 (en) | Bacterial ghosts for the treatment of cancer | |
| MY200499A (en) | Sulfonamide pharmaceutical composition | |
| WO2019118727A3 (en) | Rescue of the pathology of lrrk2 on lysosmes with snx25 or snx27 | |
| WO2017184670A3 (en) | Methods for treating zika virus infections | |
| MX2020013290A (es) | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. | |
| MX2015011588A (es) | Tratamiento de combinacion. | |
| WO2018060962A3 (en) | Metformin amino acid compounds and methods of using the same | |
| WO2016163818A3 (ko) | 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물 |